LESS RISK.
MORE RESULTS.

Meeting advancements in cancer care with a thoughtful, measured approach.

Cancer care innovation is improving rapidly, giving hope to millions for advanced treatments and greater survival rates. But that hope comes with an even greater need for credible assessment, trusted efficacy and a measured approach. It’s crucial to partner with a health care plan that fully understands the impact of treatment. Taking time for the serious consideration and thorough qualification needed to make the right call is nonnegotiable when offering innovative care while working to manage cost.

innovation icon

Where cancer innovation stands today.

There are hundreds of cancer types and variants, and optimal treatments can be
radically different depending on many factors like genetics, environment and stage
at diagnosis. Today’s cancer innovations are ushering in a new era of therapeutics.
But limitations, such as price and access, are still factors to consider.

30

Thirty different therapeutics were approved for new or expanded uses by the FDA from July 1, 2023, to June 30, 2024.1

49arrow68%

The overall cancer survival rate
was 49% in the mid-1970s.
It currently sits at 68%.2

Exploring and nurturing the future of cancer care.

reporting

Comprehensive Reporting

open
reporting icon
  • Taking cues from the U.S. Food and Drug Administration, any approved treatments must meet generally accepted medical standards and be both effective and safe.3
  • Access to complete data sets enhances outcomes across the entire care spectrum. So you can be confident that options you present to employees have been documented, approved and trusted by credible sources.
channel manamgent

Channel
Management

open
channel icon
  • Comprehensive care allows costs to be controlled earlier in high-cost claimants by leveraging advanced interventions and optimal health care resources.
  • Specialty drug costs are reduced when health care providers work closely with employees to assess needs, treatment efficacy and more, all while maintaining the highest quality.
cost of treatment

Cost of
Treatment

open
medical bill icon
  • Between January 1, 2015, and December 31, 2020, there were 224 cancer drug approvals across 119 individual drugs. The median annual cost of each drug was $196,000.4
  • New treatments can come with astronomical costs. It’s important to clarify the effectiveness and determine the benefits of innovations before understanding the cost-benefit analysis.
holistic health management

Holistic Health Management

open
channel icon
  • Programs like our Centers of Excellence can lead to better outcomes and experiences amid lower variance and costs.5 More than 50% of employers planned to offer a cancer-focused COE approach in 2024, and an additional 23% plan to consider it by 2026.6
  • In-house customer advocates, expanded outreach and multi-disciplinary teams supplement medical profiles and can help facilitate more comprehensive treatment.

Innovating together.

The genesis of much of this research and quality assurance involves our
C1 Innovation Lab®. The Lab interacts with the national medtech startup community to stay informed about innovative products and to determine
whether there’s a place for those products within our ecosystem.

We’re here for you, so you can be there for them.

New cancer care products and treatments can transform lives by predicting diagnoses, extending survival and improving quality of life. But, with these ambitious innovations can come great risk to weigh the safety and legitimacy of these advancements with the needs of our members. Reach out to your health care representative about safety measures in place and which Centers of Excellence are in network.

Download PDF Adobe Acrobat Icon

1 American Association for Cancer Research, “AACR Cancer Progress Report,” 2024

2 City of Hope, “What’s Driving the Improvement in U.S. Cancer Survival Rates?” cancercenter.com, January 26, 2023

3 Doug Terry Law, “How Do Health Insurers Decide if Treatment Is Experimental or Investigative?” dougterrylaw.com, May 6, 2024

4 Miloš Miljković, MD, et. al., “Cancer Drug Price and Novelty in Mechanism of Action,” Jama Network Open, December 11, 2023

5 Becker’s Hospital Review, “How a True Centers of Excellence Is Boosting Patient Experience and Quality,” beckershospitalreview.com, retrieved April 24, 2025

6 Andrew Norden, “Why Cancer Centers of Excellence May Not Be Right for Every Patient,” MedCity News, December 14, 2023